ITCI News and Press, Intra-Cellular Therapies Inc. From 01/02/24

2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and...

2023-12-29 14:12:19 ET Summary The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a challenging year, there have ...

2023-12-15 03:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-12 12:40:26 ET More on Intra-Cellular Therapies The Right Play On Intra-Cellular Therapies Intra-Cellular's Caplyta Is Well On Its Way To Being A Mental Health Blockbuster Intra-Cellular Therapies, Inc. (ITCI) Q3 2023 Earnings Call Transcript Intra-Ce...

Company presents positive results of a pre-specified patient population in Study 403 examining the effects of CAPLYTA ® (lumateperone) in patients experiencing a major depressive episode with anxious distress and mixed features. Company presents preclinical data on ITI-1549, ou...

2023-11-20 11:49:37 ET Summary Intra-Cellular Therapies, Inc. is a mid-cap biopharmaceutical company focused on developing treatments for neuropsychiatric and neurological disorders. The company's commercial asset, Caplyta, has achieved significant sales growth and is an exciting ...

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the 6th Annual Evercore ISI H...

2023-11-13 05:47:25 ET Summary Intra-Cellular Therapies shows strong financial growth, driven by Caplyta sales, with improved operational efficiency and reduced net losses. Caplyta's success in schizophrenia and bipolar depression, and its potential in Major Depressive Disorder, u...

2023-11-02 15:15:04 ET Intra-Cellular Therapies, Inc. (ITCI) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Juan Sanchez – Head-Investor Relations Sharon Mates – Chairman and Chief Executive Officer Mark Neumann &#...